{"downloaded": true, "htmlmade": false, "full": {"id": "33757440", "source": "MED", "pmid": "33757440", "pmcid": "PMC7989075", "fullTextIdList": {"fullTextId": "PMC7989075"}, "doi": "10.1186/s12885-021-08031-z", "title": "Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.", "authorString": "Janssen QP, van Dam JL, Bonsing BA, Bos H, Bosscha KP, Coene PPLO, van Eijck CHJ, de Hingh IHJT, Karsten TM, van der Kolk MB, Patijn GA, Liem MSL, van Santvoort HC, Loosveld OJL, de Vos-Geelen J, Zonderhuis BM, Homs MYV, van Tienhoven G, Besselink MG, Wilmink JW, Groot Koerkamp B, Dutch Pancreatic Cancer Group.", "authorList": {"author": [{"fullName": "Janssen QP", "firstName": "Q P", "lastName": "Janssen", "initials": "QP", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands."}}}, {"fullName": "van Dam JL", "firstName": "J L", "lastName": "van Dam", "initials": "JL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands."}}}, {"fullName": "Bonsing BA", "firstName": "B A", "lastName": "Bonsing", "initials": "BA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands."}}}, {"fullName": "Bos H", "firstName": "H", "lastName": "Bos", "initials": "H", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Medical Oncology, Tjongerschans Hospital, Heerenveen, The Netherlands."}}}, {"fullName": "Bosscha KP", "firstName": "K P", "lastName": "Bosscha", "initials": "KP", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Surgery, Jeroen Bosch Hospital, Den Bosch, The Netherlands."}}}, {"fullName": "Coene PPLO", "firstName": "P P L O", "lastName": "Coene", "initials": "PPLO", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Surgery, Maasstad Hospital, Rotterdam, The Netherlands."}}}, {"fullName": "van Eijck CHJ", "firstName": "C H J", "lastName": "van Eijck", "initials": "CHJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands."}}}, {"fullName": "de Hingh IHJT", "firstName": "I H J T", "lastName": "de Hingh", "initials": "IHJT", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands."}}}, {"fullName": "Karsten TM", "firstName": "T M", "lastName": "Karsten", "initials": "TM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands."}}}, {"fullName": "van der Kolk MB", "firstName": "M B", "lastName": "van der Kolk", "initials": "MB", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands."}}}, {"fullName": "Patijn GA", "firstName": "G A", "lastName": "Patijn", "initials": "GA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Surgery, Isala Hospital, Zwolle, The Netherlands."}}}, {"fullName": "Liem MSL", "firstName": "M S L", "lastName": "Liem", "initials": "MSL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Surgery, Medisch Spectrum Twente, Enschede, The Netherlands."}}}, {"fullName": "van Santvoort HC", "firstName": "H C", "lastName": "van Santvoort", "initials": "HC", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Surgery, Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center Utrecht, Utrecht, The Netherlands."}}}, {"fullName": "Loosveld OJL", "firstName": "O J L", "lastName": "Loosveld", "initials": "OJL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Medical Oncology, Amphia Hospital, Breda, The Netherlands."}}}, {"fullName": "de Vos-Geelen J", "firstName": "J", "lastName": "de Vos-Geelen", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Internal Medicine, Division of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht UMC+, Maastricht, The Netherlands."}}}, {"fullName": "Zonderhuis BM", "firstName": "B M", "lastName": "Zonderhuis", "initials": "BM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands."}}}, {"fullName": "Homs MYV", "firstName": "M Y V", "lastName": "Homs", "initials": "MYV", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Medical Oncology, Erasmus MC University Medical Center, Rotterdam, The Netherlands."}}}, {"fullName": "van Tienhoven G", "firstName": "G", "lastName": "van Tienhoven", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands."}}}, {"fullName": "Besselink MG", "firstName": "M G", "lastName": "Besselink", "initials": "MG", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands."}}}, {"fullName": "Wilmink JW", "firstName": "J W", "lastName": "Wilmink", "initials": "JW", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands."}}}, {"fullName": "Groot Koerkamp B", "firstName": "B", "lastName": "Groot Koerkamp", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands. b.grootkoerkamp@erasmusmc.nl."}}}, {"collectiveName": "Dutch Pancreatic Cancer Group"}]}, "dataLinksTagsList": {"dataLinkstag": ["altmetrics", "supporting_data"]}, "journalInfo": {"issue": "1", "volume": "21", "journalIssueId": "3122081", "dateOfPublication": "2021 Mar", "monthOfPublication": "3", "yearOfPublication": "2021", "printPublicationDate": "2021-03-01", "journal": {"title": "BMC cancer", "ISOAbbreviation": "BMC Cancer", "medlineAbbreviation": "BMC Cancer", "NLMid": "100967800", "ISSN": "1471-2407", "ESSN": "1471-2407"}}, "pubYear": "2021", "pageInfo": "300", "abstractText": "<h4>Background</h4>Neoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are higher, thereby possibly improving overall survival (OS). Two recent randomized trials have suggested benefit of neoadjuvant chemoradiotherapy over upfront surgery, both including single-agent chemotherapy regimens. Potentially, the multi-agent FOLFIRINOX regimen (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) may further improve outcomes in the neoadjuvant setting for localized pancreatic cancer, but randomized studies are needed. The PREOPANC-2 trial investigates whether neoadjuvant FOLFIRINOX improves OS compared with neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer patients.<h4>Methods</h4>This nationwide multicenter phase III randomized controlled trial includes patients with pathologically confirmed resectable and borderline resectable pancreatic cancer with a WHO performance score of 0 or 1. Resectable pancreatic cancer is defined as no arterial and\u2009\u2264\u200990 degrees venous involvement; borderline resectable pancreatic cancer is defined as \u226490 degrees arterial and\u2009\u2264\u2009270 degrees venous involvement without occlusion. Patients receive 8\u2009cycles of neoadjuvant FOLFIRINOX chemotherapy followed by surgery without adjuvant treatment (arm A), or 3\u2009cycles of neoadjuvant gemcitabine with hypofractionated radiotherapy (36\u2009Gy in 15 fractions) during the second cycle, followed by surgery and 4\u2009cycles of adjuvant gemcitabine (arm B). The primary endpoint is OS by intention-to-treat. Secondary endpoints include progression-free survival, quality of life, resection rate, and R0 resection rate. To detect a hazard ratio of 0.70 with 80% power, 252 events are needed. The number of events is expected to be reached after inclusion of 368 eligible patients assuming an accrual period of 3\u2009years and 1.5\u2009years follow-up.<h4>Discussion</h4>The PREOPANC-2 trial directly compares two neoadjuvant regimens for patients with resectable and borderline resectable pancreatic cancer. Our study will provide evidence on the neoadjuvant treatment of choice for patients with resectable and borderline resectable pancreatic cancer.<h4>Trial registration</h4>Primary registry and trial identifying number: EudraCT: 2017-002036-17 . Date of registration: March 6, 2018. Secondary identifying numbers: The Netherlands National Trial Register - NL7094 , NL61961.078.17, MEC-2018-004.", "affiliation": "Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands.", "publicationStatus": "epublish", "language": "eng", "pubModel": "Electronic", "pubTypeList": {"pubType": ["Clinical Trial Protocol", "Clinical Trial, Phase III", "Comparative Study", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"]}, "grantsList": {"grant": [{"grantId": "10955", "agency": "KWF Kankerbestrijding", "orderIn": "0"}, {"grantId": "843004108", "agency": "ZonMw", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Pancreatic Neoplasms", "meshQualifierList": {"meshQualifier": [{"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Fluorouracil", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Leucovorin", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Deoxycytidine", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AA", "qualifierName": "analogs & derivatives", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Neoadjuvant Therapy"}, {"majorTopic_YN": "Y", "descriptorName": "Randomized Controlled Trials as Topic"}, {"majorTopic_YN": "N", "descriptorName": "Chemoradiotherapy", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Irinotecan", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Oxaliplatin", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}]}, "keywordList": {"keyword": ["Quality of life", "Randomized controlled trial", "Chemoradiotherapy", "Overall Survival", "Intention-to-treat", "Neoadjuvant", "gemcitabine", "Folfirinox", "Localized Pancreatic Cancer"]}, "chemicalList": {"chemical": [{"name": "irinotecan", "registryNumber": "7673326042"}, {"name": "gemcitabine", "registryNumber": "B76N6SBZ8R"}, {"name": "Leucovorin", "registryNumber": "Q573I9DVLP"}, {"name": "Fluorouracil", "registryNumber": "U3P01618RT"}, {"name": "Deoxycytidine", "registryNumber": "0W860991D6"}, {"name": "oxaliplatin", "registryNumber": "04ZR38536J"}, {"name": "folfirinox", "registryNumber": "0"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1186/s12885-021-08031-z"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7989075"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7989075?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "0", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "eudract"}, "dateOfCompletion": "2021-05-10", "dateOfCreation": "2021-03-24", "firstIndexDate": "2021-03-25", "fullTextReceivedDate": "2021-03-27", "dateOfRevision": "2021-05-10", "electronicPublicationDate": "2021-03-23", "firstPublicationDate": "2021-03-23"}, "htmllinks": "https://europepmc.org/articles/PMC7989075", "abstract": "<h4>Background</h4>Neoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are higher, thereby possibly improving overall survival (OS). Two recent randomized trials have suggested benefit of neoadjuvant chemoradiotherapy over upfront surgery, both including single-agent chemotherapy regimens. Potentially, the multi-agent FOLFIRINOX regimen (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) may further improve outcomes in the neoadjuvant setting for localized pancreatic cancer, but randomized studies are needed. The PREOPANC-2 trial investigates whether neoadjuvant FOLFIRINOX improves OS compared with neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer patients.<h4>Methods</h4>This nationwide multicenter phase III randomized controlled trial includes patients with pathologically confirmed resectable and borderline resectable pancreatic cancer with a WHO performance score of 0 or 1. Resectable pancreatic cancer is defined as no arterial and\u2009\u2264\u200990 degrees venous involvement; borderline resectable pancreatic cancer is defined as \u226490 degrees arterial and\u2009\u2264\u2009270 degrees venous involvement without occlusion. Patients receive 8\u2009cycles of neoadjuvant FOLFIRINOX chemotherapy followed by surgery without adjuvant treatment (arm A), or 3\u2009cycles of neoadjuvant gemcitabine with hypofractionated radiotherapy (36\u2009Gy in 15 fractions) during the second cycle, followed by surgery and 4\u2009cycles of adjuvant gemcitabine (arm B). The primary endpoint is OS by intention-to-treat. Secondary endpoints include progression-free survival, quality of life, resection rate, and R0 resection rate. To detect a hazard ratio of 0.70 with 80% power, 252 events are needed. The number of events is expected to be reached after inclusion of 368 eligible patients assuming an accrual period of 3\u2009years and 1.5\u2009years follow-up.<h4>Discussion</h4>The PREOPANC-2 trial directly compares two neoadjuvant regimens for patients with resectable and borderline resectable pancreatic cancer. Our study will provide evidence on the neoadjuvant treatment of choice for patients with resectable and borderline resectable pancreatic cancer.<h4>Trial registration</h4>Primary registry and trial identifying number: EudraCT: 2017-002036-17 . Date of registration: March 6, 2018. Secondary identifying numbers: The Netherlands National Trial Register - NL7094 , NL61961.078.17, MEC-2018-004.", "Keywords": ["Quality of life", "Randomized controlled trial", "Chemoradiotherapy", "Overall Survival", "Intention-to-treat", "Neoadjuvant", "gemcitabine", "Folfirinox", "Localized Pancreatic Cancer"], "pdflinks": "https://europepmc.org/articles/PMC7989075?pdf=render", "journaltitle": "BMC cancer", "title": "Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial."}